Cyclopharm (ASX:CYC) has announced the publication of the first US-based study highlighting the clinical utility and operational benefits of its proprietary Technegas technology.
The paper compares Technegas to current US ventilation imaging radiopharmaceuticals used in lung transplant evaluation.
The study, which follows last year’s US FDA's approval of Technegas, was written independently by leading clinicians at Washington University’s Mallinckrodt Institute of Radiology in St Louis. It highlights Technegas’ clinical efficacy compared to 133- Xenon (Xenon), the current US ventilation imaging standard used in lung transplant evaluation.
The study, 'Comparability of Quantifying Relative Lung Ventilation with Inhaled 99mTc-Technegas and 133Xe in Patients Undergoing Pre-lung Transplant Evaluation', analysed 74 patients and confirmed Technegas' effectiveness and efficiency in surgical planning for lung transplant patients.
Cyclopharm said the study further underscores the potential for Technegas to be adopted for a broader range of respiratory conditions in the US healthcare market and beyond.
James McBrayer, the managing director and CEO of Cyclopharm, said, “This groundbreaking study, wholly driven by clinicians, clearly illustrates the transformative potential of Technegas across the US healthcare market. By validating its clinical equivalence to Xenon and highlighting its operational benefits, this independent research paves the way for broad adoption of Technegas across a range of respiratory conditions in the world’s largest healthcare market. We are committed to delivering innovative, life-changing diagnostic solutions while driving long-term shareholder value.
“The results also emphasise how Technegas can not only replace existing radiopharmaceuticals but also challenge higher-radiation alternatives like CTPA [Computed Tomography Pulmonary Angiogram], enhancing patient safety, care and clinical outcomes.”
